Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

Significance Few patients with pancreatic cancer survive longer than 5 y, in part because most patients are identified only after their disease has progressed to an advanced stage. In this study, we show how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity. The combination of the ctDNA and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.

• CN
  Conrad N. Hilton Foundation
• JT
  John Templeton Foundation
• CF
  Commonwealth Foundation
• LF
  Lustgarten Foundation
• VA
  Virginia and D.K. Ludwig Fund for Cancer Research
• UO
  University of Pittsburgh
• NI
  National Institutes of Health

  Awards: U01CA152753, P50-CA62924, CA-06973, GM-07309, CA006973, CA062924, P30-CA006973, P50-CA062924, CA102701, P50-CA102701
• MR
  Medical Research Council
• NH
  National Health and Medical Research Council